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Background
Lymphedema as a sequelae of breast 
cancer treatment is thought to affect 
between 13-42% of patients, making it a 
major concern for both patients and 
physicians.1,2 As oncologic survivorship 
and lifespan expectancies improve, 
understanding and management of this 
potential side effect becomes 
increasingly important.3
Inflammatory breast cancer (IBC) is an 
aggressive disease that comprises 1-5% 
of invasive breast cancer diagnoses.4
The standard of care consists of 
trimodality treatment—neoadjuvant 
chemotherapy (NCT), modified radical 
mastectomy (MRM), and radiotherapy 
(XRT). As both MRM and XRT are 
considered risk factors for lymphedema 
development, IBC patients are at an 
increased risk for lymphedema.
Methods
Patients with stage III and stage IV IBC 
treated at MD Anderson Cancer Center 
between 2016-2019 were identified from a 
prospective database (N=173). 
Lymphedema measurements captured in 
the medical record were reviewed. 
Patients were excluded if there were no 
lymphedema measurements available or 
they underwent bilateral axillary surgery 
(N=85). 
Lymphedema was defined as a >10% 
increase in perometer readings in upper 
extremity volumes comparing the baseline 
measurement to the highest reported 
volume. Patients with preoperative and 
follow up lymphedema measurements 
were included in the analysis, with a final 
sample size of 84 patients. Demographic, 
clinical and pathologic factors, oncologic 
outcomes, lymphedema symptoms and 
objective lymphedema measurements 
were recorded for the entire cohort and 
compared among patients who did and 
did not develop lymphedema. 
Future Directions
• Determine time to lymphedema development 
in this population
• Further analysis to understand factors 
associated with lymphedema 
• Explore how subjective assessment of 
lymphedema correlates to perometry
measurements
• Evaluate lymphedema management 
strategies (e.g., physical therapy, 
lymphovenous bypass, lymph node transfer) 
and impact on % volume increase and time 
to lymphedema development
Conclusions
Preliminary results suggest a uniquely 
high incidence of lymphedema in IBC 
patients, especially in subjective ratings of 
lymphedema development. Given this 
strong likelihood of lymphedema 
development, lymphedema management 
strategies should be explored for IBC 
patients.
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Objective
The objective of this study was to 
evaluate the incidence of lymphedema 
in IBC patients. 
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Results
• The incidence of lymphedema in this 
IBC cohort was 47.6%
• Average volume increase in patients 
who developed lymphedema was 26.6%
• Subjective reports of lymphedema were 
almost universal in patients who 
developed lymphedema (85% 
heaviness and 100% swelling) 
compared to lower values in patients 
with no lymphedema (43.2% heaviness 
and 52.3% swelling)
• Similar age and BMI among patients 
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Figure 2.  Clinical signs of IBC in a patient’s left breast, 
including edema, skin thickening, peau d’orange, and 
erythema. Published by Simons et al.4
Figure 3. Clinical signs of lymphedema in a 
patient following mastectomy, ALND, and 
radiotherapy. Published by Engel et al.5





Table 1. Demographic, clinical-pathologic factors, outcomes and lymphedema assessment for 
IBC patients receiving preoperative and at least one follow up lymphedema volume 
measurement from 2016-2019 (N=84). 
Entire cohort Lymphedema No lymphedema
N=84 N= 40 (47.6%) N= 44 (52.4%)






















































































































Average % Volume change of 










Median follow up 18 (1-136) 23 (5-48) 9 (1-136)
Recurrence:
Local-regional
Distant
Both
2 (2.3%)
25 (29.8%)
3 (3.6%)
1 (2.5%)
14 (35%)
2 (5%)
1 (2.2%)
11 (25%)
1 (2.2%)
Death:
Yes
No
14 (16.7%)
70 (83.3%)
4 (10%)
36 (90%)
10 (22.7%)
34 (77.3%)
